Currently, there are several existing FDA - approved blocking drugs for this protein including rapamycin, currently used primarily as an immunosuppressant after solid organ transplantation. (sciencedaily.com)
Research led by a University of Cincinnati (UC) scientist shows the impact of acute kidney injury requiring dialysis (AKI - D) on patients receiving non-renal solid organ transplantation (NRSOT), including cardiac and liver transplantation. (sciencedaily.com)
As a result, they are currently being investigated as a cellular therapeutic for the treatment of autoimmune diseases and long - term patient and graft survival following solid organ transplantation, and allogeneic hematopoietic stem cell transplantation. (rndsystems.com)